TOBRADEX ST Rx
Generic Name and Formulations:
Tobramycin 0.3%, dexamethasone 0.05%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for TOBRADEX ST:
Ocular inflammation associated with infection or risk thereof.
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop every 2hrs for 1st 24–48 hrs, then every 4–6 hrs. Reduce dose as condition improves; max 20mL for initial ℞.
Viral, fungal, or mycobacterial infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections, intraocular pressure and cataracts in prolonged use. Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Aminoglycoside + steroid.
Local effects (eg, eye pain, eyelids pruritus, eyelid edema, conjunctival hyperemia or erythema), increased intraocular pressure, glaucoma, cataracts, corneal perforations, optic nerve damage, delayed wound healing, secondary infection.
Susp—2.5mL, 5mL, 10mL; Oint—3.5g
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness